Key Takeaways:
- Innovative Clinical Study Launch: Newel Health initiates a groundbreaking study, “NWL-SOT-CS-001,” for Parkinson’s disease, focusing on real-world data.
- Enhancing Treatment Strategies: Utilizing Soturi mobile app and smart devices for data collection, aiming to refine Parkinson’s medication plans.
- Significant Funding and Support: The study receives generous funding from The Michael J. Fox Foundation and involves three esteemed centers in Italy.
Introduction
Newel Health, a forefront digital therapeutic solution provider, has recently unveiled a revolutionary clinical study named “NWL-SOT-CS-001.” This initiative is set to leverage real-world data to significantly enhance treatment strategies for Parkinson’s disease.
The Genesis of NWL-SOT-CS-001
Recruitment and Onboarding
This study, which began its recruitment phase in Salerno, Italy, involves three centers, including the University Hospital San Giovanni di Dio e Ruggi d’Aragona in Salerno, and two centers in Rome. It aims to collect free-living data to understand patients’ daily challenges and medication responses.
Funded by The Michael J. Fox Foundation
The Michael J. Fox Foundation for Parkinson’s Research has generously funded this initiative, recognizing its potential to transform Parkinson’s disease treatment.
Leveraging Real-World Data
Free-Living Data Collection
The study prioritizes gathering data from patients’ everyday lives to capture the true essence of their challenges and medication adherence. This approach bridges the gap between clinical monitoring and real-life experiences of Parkinson’s patients.
Utilizing Digital Tools
The Soturi mobile app, combined with a wearable smart device, plays a crucial role in seamless data capture over a six-month period. This digital methodology is key to understanding symptom patterns and optimizing treatment plans.
Aiming for Treatment Optimization
Reducing OFF Periods
By analyzing medication’s impact on symptom fluctuations, the study aspires to develop a model for refining medication schedules, potentially reducing the duration of OFF periods in Parkinson’s patients.
The Role of Key Investigators
Prof. Maria Teresa Pellecchia’s Vision
Prof. Maria Teresa Pellecchia, the Principal Investigator from the University Hospital San Giovanni di Dio e Ruggi d’Aragona, emphasizes the study’s focus on accurate identification and remote monitoring of Parkinson’s symptoms in real-world settings.
Insights from Dr. Clelia Pellicano
Dr. Clelia Pellicano, another Principal Investigator, highlights the importance of ecological data over conventional clinical visit insights, aiming for a comprehensive understanding of patient symptomatology.
The Future of Parkinson’s Disease Research
Giovanni Gentile’s Perspective
Giovanni Gentile, Clinical Trial Manager at Newel Health, speaks about the significance of this study in the context of digital data and endpoint collection. He underscores the importance of real-world data in capturing the nuanced variability in Parkinson’s disease.
Expanding Beyond Traditional Monitoring
This study represents a crucial step towards comprehensive and impactful research outcomes, moving beyond traditional monitoring methods.
Conclusion
Newel Health’s innovative approach in the “NWL-SOT-CS-001” clinical study marks a significant milestone in the management and treatment of Parkinson’s disease. By harnessing real-world data and leveraging digital technologies, this study paves the way for more effective, personalized treatment strategies.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at pitch@businesstoday.news to get started!
